-

PHAXIAM: Monthly Information Related to Total Number of Voting Rights and Shares Composing the Share Capital – December 31, 2024

Article 223-16 of general regulation of French Autorité des Marchés Financiers

LYON, France--(BUSINESS WIRE)--Regulatory News:

PHAXIAM (Paris:PHXM):

Listing market: Euronext Paris (Market segment C - ISIN Code: FR001400K4B1- Symbol: PHXM)
Website : www.phaxiam.com

Date

Total of shares composing the share capital

Total of brut (1) voting rights

 

Total of net (2) voting rights

 

December 31, 2023

6 075 105

6 226 982

6 226 733

January 31, 2024

6 075 105

6 227 002

6 226 753

February 29, 2024

6 075 105

6 226 951

6 226 702

March 29, 2024

6 075 105

6 226 938

6 226 689

April 30, 2024

6 075 105

6 226 932

6 226 683

May 31, 2024

6 075 105

6 226 989

6 226 740

July 1, 2024

9 980 668

10 132 597

10 132 348

October 8, 2024

10 013 719

10 165 848

10 165 599

October 31, 2024

10 013 719

10 165 846

10 165 597

November 29, 2024

10 013 719

10 166 025

10 165 776

December 31, 2024

10 050 675

10 202 881

10 202 632

(1) Gross voting rights number (or « theoretical » voting rights) is used as a basis for calculating the crossing of the threshold. In accordance with article 223-11 of general regulation of Autorité des Marchés Financiers, this number is calculated on the basis of all shares carrying the single and double voting rights, including shares without voting rights.
(2) Without treasury shares.

Contacts

PHAXIAM

Phaxiam

BOURSE:PHXM

Release Versions

Contacts

PHAXIAM

More News From Phaxiam

PHAXIAM Therapeutics Announces the Suspension of Trading in Its Shares Until Delisting

LYON, France--(BUSINESS WIRE)--Regulatory News: PHAXIAM Therapeutics (Euronext: PHXM - FR001400K4B1), hereinafter referred to as “the Company” or “PHAXIAM,” a biopharmaceutical company specializing in the development of innovative treatments for resistant bacterial infections, asked Euronext to suspend trading of its shares listed on the Euronext Paris market starting today, Wednesday, June 18, 2025, before the market opens. Trading in PHAXIAM shares (FR001400K4B1) will remain suspended until t...

PHAXIAM Therapeutics Announces Judicial Liquidation and Delisting

LYON, France--(BUSINESS WIRE)--Regulatory News: PHAXIAM Therapeutics (Euronext: PHXM - FR001400K4B1), hereinafter referred to as “the Company” or “PHAXIAM,” a biopharmaceutical company specializing in the development of innovative treatments for resistant bacterial infections, today announces that the Lyon Commercial Court has ordered the judicial liquidation (liquidation judiciaire) of the Company on June 11, 2025. As part of the judicial receivership proceedings (redressement judiciaire), two...

PHAXIAM Therapeutics: New Postponement of the Offer Review Hearing

LYON, France--(BUSINESS WIRE)--Regulatory News: PHAXIAM Therapeutics (Euronext: PHXM - FR001400K4B1), a biopharmaceutical company ("the Company" or "PHAXIAM") developing innovative treatments for severe and resistant bacterial infections, announces that the Lyon Commercial Court (“Tribunal des activités économiques de Lyon”) decided, during a hearing held on June 4, 2025, to postpone the offer review hearing and has set a new hearing date for Wednesday, June 11, 2025. At the end of the bid exam...
Back to Newsroom